Welcome to LookChem.com Sign In|Join Free
  • or
3-CHLORO-2-OXOPROPYLIDENE TRIPHENYLPHOSPHORANE, with the molecular formula C18H15ClO2P, is a yellow to brown colored chemical compound. It is widely recognized for its reactivity in organic synthesis, where it forms phosphoranes with various organic compounds. These phosphoranes are crucial intermediates in the synthesis of a range of organic compounds. 3-CHLORO-2-OXOPROPYLIDENE TRIPHENYLPHOSPHORANE also plays a significant role in the preparation of phosphorus ylides, which are instrumental in the Wittig reaction for the synthesis of alkenes. Moreover, 3-CHLORO-2-OXOPROPYLIDENE TRIPHENYLPHOSPHORANE has garnered interest in the field of medicinal chemistry and drug discovery for its potential applications.

13605-66-8

Post Buying Request

13605-66-8 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

13605-66-8 Usage

Uses

Used in Organic Synthesis:
3-CHLORO-2-OXOPROPYLIDENE TRIPHENYLPHOSPHORANE is used as a reagent for its ability to react with a variety of organic compounds, leading to the formation of phosphoranes. These phosphoranes are vital intermediates in the synthesis of numerous organic compounds, making 3-CHLORO-2-OXOPROPYLIDENE TRIPHENYLPHOSPHORANE an essential tool in organic chemistry.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 3-CHLORO-2-OXOPROPYLIDENE TRIPHENYLPHOSPHORANE is utilized for its potential applications in medicinal chemistry and drug discovery. Its unique reactivity and ability to form phosphoranes contribute to the development of new pharmaceutical compounds and the enhancement of existing ones.
Used in the Wittig Reaction:
3-CHLORO-2-OXOPROPYLIDENE TRIPHENYLPHOSPHORANE is used as a precursor in the preparation of phosphorus ylides, which are key components in the Wittig reaction. This reaction is a widely used method for the synthesis of alkenes, a class of compounds that are fundamental in organic chemistry and have broad applications across various industries, including pharmaceuticals, agrochemicals, and materials science.

Check Digit Verification of cas no

The CAS Registry Mumber 13605-66-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,6,0 and 5 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 13605-66:
(7*1)+(6*3)+(5*6)+(4*0)+(3*5)+(2*6)+(1*6)=88
88 % 10 = 8
So 13605-66-8 is a valid CAS Registry Number.
InChI:InChI=1/C21H18ClOP/c22-16-18(23)17-24(19-10-4-1-5-11-19,20-12-6-2-7-13-20)21-14-8-3-9-15-21/h1-15,17H,16H2

13605-66-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-chloro-3-(triphenyl-λ<sup>5</sup>-phosphanylidene)propan-2-one

1.2 Other means of identification

Product number -
Other names 3-chloro-1-triphenylphosphoranylidene-2-propanone

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:13605-66-8 SDS

13605-66-8Relevant academic research and scientific papers

High catalytic activity of a new Ag phosphorus ylide complex supported on montmorillonite: synthesis, characterization, and application for room temperature nitro reduction

Karami, Kazem,Rahimi, Mahzad,Dinari, Mohammad

, p. 281 - 291 (2018)

In this work, the phosphorus ylide, [PPh3CHC(O)CH2Cl], was reacted with AgNO3 to give the [Ag{C(H)PPh3C(O)CH2Cl}2]+NO3? as the product. Then, it was supported on the modified montmorillonite nanoclay to prepare a new catalyst for the reduction reaction. The structure and morphology of the nanoclay catalyst were characterized by FT-IR, X-ray powder diffraction, scanning electron microscopy, energy-dispersive X-ray analysis and transmission electron microscopy techniques; also, the content of silver was obtained by inductively coupled plasma analyzer. This composition was exploited to study its catalytic activity in the reduction in aromatic nitro compounds; it displayed the high catalytic activity. Factors such as catalyst amount, solvent, temperature and reaction time were all systematically investigated to elucidate their effects on the yield of catalytic reduction in nitroarenes. This catalytic system exhibited high activity toward aromatic nitro compounds under mild conditions. The catalyst was reused five times without any significant loss in its catalytic activity.

Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraints

Audia, James E.,Barberis, Mario,Beck, James P.,Boggs, Leonard N.,Borders, Anthony R.,Boyer, Robert D.,Brier, Richard A.,Erickson, Jon A.,Garcia-Losada, Pablo,Green, Steven J.,Hembre, Erik J.,Hendle, J?rg,Lopez, Jose E.,Mathes, Brian M.,May, Patrick C.,Mergott, Dustin J.,Minguez, Jose Miguel,Monk, Scott A.,Porter, Warren J.,Rankovic, Zoran,Shi, Yuan,Stout, Stephanie L.,Timm, David E.,Watson, Brian M.,Winneroski, Leonard L.,Yang, Zhixiang

, (2019)

Inhibition of BACE1 has become an important strategy in the quest for disease modifying agents to slow the progression of Alzheimer's disease. We previously reported the fragment-based discovery of LY2811376, the first BACE1 inhibitor reported to demonstrate robust reduction of human CSF Aβ in a Phase I clinical trial. We also reported on the discovery of LY2886721, a potent BACE1 inhibitor that reached phase 2 clinical trials. Herein we describe the preparation and structure activity relationships (SAR) of a series of BACE1 inhibitors utilizing trans-cyclopropyl moieties as conformational constraints. The design, details of the stereochemically complex organic synthesis, and biological activity of these BACE1 inhibitors is described.

FLUORESCENT SYSTEMS FOR BIOLOGICAL IMAGING AND USES THEREOF

-

, (2021/02/12)

The invention relates to compounds of formula I, in which Y, Ar1, Ar2, X, R1 and R2 are defined herein, and to their use in a variety of biological imaging techniques and therapeutic methods. In aspects, the invention relates to conjugates comprising the compounds of formula I and their associated uses and therapeutic uses.

AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

-

, (2015/07/22)

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

-

Paragraph 0550, (2015/09/22)

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

One-pot eschenmoser episulfide contractions in DMSO: Applications to the synthesis of fuligocandins A and B and a number of vinylogous amides

Pettersson, Birgitta,Hasimbegovic, Vedran,Bergman, Jan

, p. 1554 - 1561 (2011/05/19)

Practical total syntheses of the natural products fuligocandin A (2a) and fuligocandin B (3) have been achieved through a convergent strategy depending on the Eschenmoser episulfide contraction as a key step. Conducting the reaction in DMSO proved to be an efficient and general method for the synthesis of a variety of vinylogous amides, such as azepan-2- ylidenepropan-2-one. 2011 American Chemical Society.

Total synthesis of fuligocandines A and B

Pettersson, Birgitta,Hasimbegovic, Vedran,Bergman, Jan

scheme or table, p. 238 - 239 (2010/03/24)

A practical synthesis of the biologically active cycloanthranilylproline derivatives fuligocandines A and B is described, starting from l-proline and isatoic anhydride, employing an Eschenmoser episulfide contraction as the key step.

A convergent total synthesis of (+)-febrifugine

Sieng, Bora,Ventura, Oscar Lozano,Bellosta, Véronique,Cossy, Janine

scheme or table, p. 1216 - 1218 (2009/04/04)

Febrifugine was synthesized in ten steps from N-Boc 4-aminobutan-1-ol by a convergent approach. Georg Thieme Verlag Stuttgart.

New nitrogenated siloxy butadienes from 1,3-dichloroacetone

Alonso, Dulce,Caballero, Esther,Medarde, Manuel,Tomé, Fernando

, p. 907 - 910 (2008/02/03)

New 1-formamido-2-siloxy-1,3-butadienes have been generated from 1,3-dichloroacetone by means of phosphorane formation, formamido substitution, Wittig olefination and silylation. The procedure demonstrates the utility and versatility of this methodology for the formation of polysubstituted dienes, designed as useful building blocks for the synthesis of polycyclic alkaloids and related analogues.

Synthesis of 3-oxooxa- and 3-oxoazacycloalk-4-enes by ring-closing metathesis. Application to the synthesis of an inhibitor of cathepsin K

Taillier, Catherine,Hameury, Thomas,Bellosta, Véronique,Cossy, Janine

, p. 4472 - 4490 (2008/02/01)

3-Oxooxa- and 3-oxoazacycloalk-4-enes were obtained with good yield from 1-(ω-alkenyloxy)- and 1-(ω-alkenylamino)-but-3-en-2-ones by using a ring-closing metathesis. This methodology has been used to synthesize an inhibitor of cathepsin K.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 13605-66-8